Roche extends the tender offer for Spark Therapeutics, Inc.’s shares
Category: #headlines  By Akshay Kedari  Date: 2019-08-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche extends the tender offer for Spark Therapeutics, Inc.’s shares

The extended tender would provide additional time for the U.S. FTC and U.K. CMA to complete their prior disclosed evaluations of Roche’s acquisition of Spark. 

Swiss healthcare giant, Roche Holding AG have recently announced that it has stretched the offering period of its formerly announced tender offer to purchase all the outstanding shares of common stock of U.S. pharmaceutical company, Spark Therapeutics, Inc. for a reasonable price of $114.50 per share.

According to reliable sources, Citibank, N.A., the depository for the offer, had advised Roche that, as of July 30th, around 9,715,086 shares of Spark had been validly tendered and received, leaving an estimated 25.2% of Spark’s shares as outstanding.

Stockholders who have already given their shares of Spark, do not have to re-tender their shares or take any other action as a result of the extension, suggest reports.

Moreover, closing of the tender offer would depend upon customary closing conditions, including the termination of the valid waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Meanwhile, MacKenzie Partners, Inc., information agent for the offer would request for documents, while questions regarding the offer would be diverted to the company.

For the record, Spark Therapeutics is a startup pharmaceutical company that is focused on developing, discovering and delivering gene therapies. The company aims on developing medicines for genetic diseases, including blindness, lysosomal storage disorders, haemophilia and neurodegenerative diseases.

As for Roche, it is focused on progressing science to improve people’s health. The availability of diagnostics and pharmaceuticals under one roof has helped Roche become a leader in personalized healthcare. The company is also a frontrunner in diabetes management and a global leader in vitro diagnostics and tissue-based cancer diagnostics.

Headquartered in Basel, Switzerland, the Roche Group is spread over 100 countries with a workforce of about 94,000 employees recorded last year. Additionally, in 2018, Roche invested a total of CHF 11 billion in R&D and managed to record a sale of CHF $56.8 billion, cite sources.

Source Credit: https://www.globenewswire.com/news-release/2019/07/31/1894176/0/en/Roche-and-Spark-Therapeutics-Inc-announce-extension-of-tender-offer-for-shares-of-Spark-Therapeutics-Inc.html

 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

WiseTech Global acquires U.S. logistic company Depot Systems
WiseTech Global acquires U.S. logistic company Depot Systems
By Akshay Kedari

Depot Systems will remain under MD Wally Morris’s leadership and will continue to offer container yard management solutions to its clients in the U.S. Global logistics solutions group, WiseTech Global has recently announced the acquisition of...

JPMorgan aims to expand use of blockchain to improve payment systems
JPMorgan aims to expand use of blockchain to improve payment systems
By Akshay Kedari

The company has developed a function for verifying in real time whether a payment was being transferred into a valid account Reports confirm that JPMorgan Chase is planning to expand its deployment of blockchain technology for improving the payment ...

Cafe Coffee Day (CCD) to initiate stake sale talks with Coca-Cola
Cafe Coffee Day (CCD) to initiate stake sale talks with Coca-Cola
By Akshay Kedari

Coca-Cola is trying to expand its influence in the café space as its primary product is experiencing a slump. Indian café chain operator, Coffee Day Group is reportedly seeking to restart its negotiation with beverage giant Coca-C...